FDA advisors said that more data are needed to fully understand if there are broader safety concerns related to use of respiratory syncytial virus (RSV ... are an excellent vector, in a way ...

Every year, millions of infants are infected by a little-known virus that is the most common cause of respiratory disease in children. Respiratory syncytial virus (RSV) (Fig. 1) causes a spectrum ...

Those recommendations on Wednesday were: — People 50 to 59 should be able to get vaccinated against respiratory syncytial ...

Meeting, held April 24–28 in Honolulu, reveals that young children with chronic conditions are more likely to be hospitalized ...

For the second time this summer, cases of RSV — or Respiratory Syncytial Virus — are unusually high in parts of the United States. While the illness is common and the typical cause of ...

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector ... and respiratory syncytial virus (RSV).

A single dose of the RSVPreF3 OA vaccine offers strong protection against RSV-related lower respiratory tract disease in ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.